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Abstract 
Background: Heart failure disease management programs can influence medical 
resource use and quality-adjusted survival. Because projecting long-term costs and survival is 
challenging, a consistent and valid approach to extrapolating short-term outcomes would be 
valuable. 
Methods: We developed the Tools for Economic Analysis of Patient Management 
Interventions in Heart Failure (TEAM-HF) Cost-Effectiveness Model, a Web-based simulation 
tool designed to integrate data on demographic, clinical, and laboratory characteristics, use of 
evidence-based medications, and costs to generate predicted outcomes. Survival projections are 
based on a modified Seattle Heart Failure Model (SHFM). Projections of resource use and 
quality of life are modeled using relationships with time-varying SHFM scores. The model can 
be used to evaluate parallel-group and single-cohort designs and hypothetical programs. 
Simulations consist of 10,000 pairs of virtual cohorts used to generate estimates of resource use, 
costs, survival, and incremental cost-effectiveness ratios from user inputs. 
Results: The model demonstrated acceptable internal and external validity in replicating 
resource use, costs, and survival estimates from 3 clinical trials. Simulations to evaluate the cost-
effectiveness of heart failure disease management programs across 3 scenarios demonstrate how 
the model can be used to design a program in which short-term improvements in functioning and 
use of evidence-based treatments are sufficient to demonstrate good long-term value to the health 
care system. 
Conclusion: The TEAM-HF Cost-Effectiveness Model provides researchers and 
providers with a tool for conducting long-term cost-effectiveness analyses of disease 
management programs in heart failure.  
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Introduction 
Although economic evaluations of heart failure disease management programs are 
plentiful, a recent review identified only 2 formal cost-effectiveness analyses that extrapolated 
beyond a trial’s follow-up period.1 Without extrapolation, the value of a disease management 
program may be underestimated. For example, an analysis of the South Texas Congestive Heart 
Failure Disease Management Project reported an incremental cost-effectiveness ratio greater than 
$100,000 per quality-adjusted life-year (QALY) within the trial’s 18-month follow-up period.2 
However, extension of the time horizon with a Markov model structured using New York Heart 
Association (NYHA) classification reduced the incremental cost-effectiveness ratio to less than 
$50,000 per QALY.3 This example demonstrates the importance of accounting for all 
downstream costs and health benefits attributable to an intervention to provide a fair assessment 
of its cost-effectiveness. 
With support from the National Institute of Nursing Research, we developed user-
friendly tools to facilitate high-quality economic evaluations of patient-focused interventions. In 
our project, Tools for Economic Analysis of Patient Management Interventions in Heart Failure 
(TEAM-HF), we developed a costing tool4 and a cost-effectiveness model. In this paper, we 
describe the TEAM-HF Cost-Effectiveness Model, a generalizable, Web-based tool designed to 
assist researchers, administrators, and providers in estimating short-term or long-term estimates 
of resource use, costs, and cost-effectiveness of disease management programs or other care 
strategies in heart failure. We then compare predicted estimates of resource use and costs from 
the model to estimates from 3 studies to evaluate the internal and external validity of the model. 
We also evaluate the potential cost-effectiveness of 3 disease management scenarios to 
demonstrate how the model can be used to design more cost-effective interventions.  
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Methods 
Web-Based Application 
To maximize accessibility, we developed a freely available Web-based tool that allows 
users to select modeling options and specify inputs in an integrated simulation model. The tool 
takes the form of a series of input pages (Table 1). It includes 3 study design options: 
hypothetical scenario; parallel groups; and single cohort (Supplemental Figure A). 
The hypothetical scenario design option allows the user to generate simulated outcomes 
for 2 patient groups with different clinical and treatment characteristics. The parallel groups 
design option is appropriate for randomized trials or other studies with 2 comparator groups. The 
user prescribes observed counts of resource use and deaths for the observed follow-up period. 
After the observation period, simulated outcomes are generated over the time period specified by 
the user. The single cohort design option allows users to evaluate a program that has already 
been implemented. The user prescribes clinical and treatment characteristics for the patients 
before and after their participation in the program. 
Additional input pages correspond to patients’ demographic and clinical characteristics, 
laboratory test results, use of diuretics, and use of evidence-based medications and devices that 
represent parameters in the prognostic model integrated with the tool. The user can also prescribe 
unit costs for medications, hospitalizations, emergency department visits, and outpatient visits. 
A cost-effectiveness analysis requires users to account for the costs associated with a 
disease management program. Therefore, the user must specify the duration and monthly cost of 
the program. If the program includes an “intense” phase and a less intense “maintenance” phase, 
the user can specify the duration and monthly cost for each phase. The user can also extend the 
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monthly costs of the program indefinitely (ie, until death). The final inputs relate to the time 
horizon for the simulations, discount rates, and options for reporting. 
 
Model Structure 
We selected the Seattle Heart Failure Model (SHFM) as the underlying prognostic model, 
because its external validity has been tested in 14 clinical cohorts, more than any other model for 
heart failure.5,6 Also, its inclusion of multiple clinical and laboratory variables and the integration 
of treatment effects for evidence-based therapies allows our model to account for the effects of 
disparate disease management programs or treatment care strategies. For example, the same 
model could be used to evaluate a program to improve physical functioning or a program to 
increase the use of β-blockers. 
 
Modifications to the SHFM 
In the original SHFM publication, an exponential hazard function was suggested to 
generate long-term survival estimates.5 An exponential hazard function assumes a constant 
mortality rate, which can lead to overestimation of survival. Therefore, we replaced the 
exponential function with a calibrated competing risks regression model in which the baseline 
hazard for each mode of death was assumed to follow a Gompertz distribution, under the 
proportional hazards assumption, using data representing 7151 patients from 4 clinical trials and 
prospective observational cohorts.6 The shape parameters for heart failure death and non–heart 
failure death were positive (0.281 and 0.204, respectively), indicating increasing risk over time, 
whereas the parameter for sudden death was approximately equal to zero (< .001), indicating 
constant risk. The fitted survival model enables us to calculate expected survival time for any 
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SHFM score. Figure 1 shows the overall survival curves for integer SHFM scores; the 
corresponding table displays the mean survival estimates. See the Online-Only Supplement for 
details. 
We also modified the treatment effects of several medication classes in the SHFM. First, 
we removed the effect of statins on mortality risk to reflect findings from 2 clinical trials.7,8 
Second, although meta-analyses support the benefits of angiotensin-converting enzyme (ACE) 
inhibitors and angiotensin II receptor blockers (ARBs) in heart failure, clinical trials have not 
demonstrated additive treatment effects of ARBs with ACE inhibitors.9-11 Therefore, we 
modified the SHFM to apply a hazard ratio of 0.77 for patients treated with an ACE inhibitor 
and/or ARB.12 Third, we reduced the treatment benefit of aldosterone antagonists by replacing 
the hazard ratio of 0.70 from the Randomized Aldactone Evaluation Study (RALES) with a 
hazard ratio of 0.76 from the Eplerenone in Mild Patients Hospitalization and Survival Study in 
Heart Failure (EMPHASIS-HF),13 an effect consistent with an earlier meta-analysis.14 
 
Mode of Death 
Resource use, associated medical costs, and health-related quality of life in the year 
before death differ markedly between patients who die from sudden death versus other causes.15 
To account for these differences, we used mathematical relationships derived from data from the 
4 cohorts described above to estimate the conditional probability of dying from heart failure, 
sudden death, or another cause as a function of time and a patient’s baseline SHFM score 
(Figure 2). We incorporated these probabilities into the model such that the assigned cause of 
death for each virtual patient was conditional on the patient’s initial SHFM score and simulated 
time of death. 
7 
 
 
Modeling Medical Resource Use and Health Utilities 
In addition to estimating survival and assigning a mode of death for each virtual patient, 
the model assigns rates of medical resource use and health utility (ie, quality of life) weights 
across time. We used data from Heart Failure: A Controlled Trial Investigating Outcomes of 
Exercise Training (HF-ACTION) to estimate relationships between SHFM scores and rates of 
medical resource use16 and health utilities.17 As expected, patients with higher SHFM scores had 
significantly higher rates of hospitalization, emergency department or urgent care visits, and 
nonurgent outpatient visits in the following year.16 We assigned cause-specific hospitalizations 
according to distributions observed in HF-ACTION. Similarly, higher SHFM scores predicted 
lower health utilities at baseline, and their mean utilities decreased at a faster rate relative to 
lower SHFM scores.17 
 
Modeling Change in SHFM Scores 
To relate the natural progression of heart failure with corresponding SHFM scores, we 
used mathematical relationships to determine the rate at which SHFM scores would have to 
increase to maintain consistency with the time-varying global hazard function (Online-Only 
Supplement). By quantifying the relationships between initial SHFM scores and SHFM scores 
across time, the model updates each virtual patient’s SHFM score each year. This approach 
allows the model to assign higher rates of resource use and lower health utilities over time. 
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Model Simulations 
Simulations consist of 10,000 Monte Carlo iterations. Each iteration represents a single 
realization of the 2 user-defined virtual patient cohorts with sample sizes specified by the user. 
For each virtual patient within a cohort, demographic, laboratory, and clinical characteristics are 
sampled from a multivariate mixed distribution based on user-prescribed inputs. The default 
values and associated correlation matrix were derived from the 4-cohort sample of 7151 patients 
described above (Supplemental Tables B1 and B2).5 
For each virtual patient, the simulated time of death is sampled from the corresponding 
SHFM score–specific survival function (Supplemental Figure 3.1). The cause of death is then 
assigned using the cumulative probabilities of death (for heart failure, sudden cardiac death, and 
other cause), conditional on the initial SHFM score and the simulated time of death (Figure 2). 
The SHFM score for each virtual patient is then updated for each subsequent year. 
Annual counts of medical resources are generated for each virtual patient using negative 
binomial regression models, in which the predicted SHFM score at the beginning of each year is 
the explanatory variable. When less than 1 year of survival remains, the explanatory variables in 
the regression models include the patient’s predicted SHFM score at the beginning of that year, 
the simulated cause of death, and the number of days alive in the final year of life 
(Supplemental Table 5.1). For each simulated year across the 10,000 Monte Carlo iterations, 
unit cost estimates are multiplied by the corresponding counts for each type of medical resource 
for each patient in each cohort. Costs in each year are then discounted and summed to calculate 
cumulative costs for each cohort. 
Utility weights are assigned to account for differences in quality of life across patients. 
Each virtual patient’s utility weight is a linear function of the patient’s corresponding time-
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adjusted SHFM score. When the user opts to allow utilities to vary (ie, “stochastic” option), each 
virtual patient’s initial utility score is sampled from a normal distribution and then decays in a 
linear fashion until the time of death. In cases for which the sampled utility weight exceeds 1, the 
value is capped at 1. 
 
Variability 
The model incorporates stochastic uncertainty, which represents differences in outcomes 
that can occur between 2 realizations of the same patient. For example, a patient with an SHFM 
score of 1.0 may have an estimated life expectancy of 5.14 years, but the sampled life 
expectancy for 2 simulated patients with the same SHFM score could be 3 months or 8 years, 
representing stochastic uncertainty. 
The user has the option to select “deterministic” or “stochastic” for SHFM coefficients, 
time of death, resource use, and utility weights. With the deterministic option, expected values 
for resource use, health utilities, and survival are assigned to virtual patients in each of the 
10,000 iterations. With the “stochastic” option, outcomes for each patient are sampled from their 
corresponding parametric distributions in each iteration, resulting in 10,000 estimates for 
resource use, cost, and survival. Corresponding 95% CIs are calculated by sorting the 10,000 
estimates in ascending order and taking the 250th and 9750th ranked values. 
 
Validation 
We applied the TEAM-HF Cost-Effectiveness Model to 3 heart failure trials to compare 
simulated and observed estimates and to demonstrate how the model can be used to reverse-
engineer a cost-effective disease management program. The inputs specified in each of the 3 
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validation tests are reported in Supplemental Table D.1. We performed the simulations using 
both the stochastic and deterministic options to demonstrate the impacts of these choices. 
 
CHIME  
The Medication Adherence in Chronic Illness: Medications, Meaning and Me (CHIME) 
pilot study tested an intervention to improve medication adherence in 86 high-risk patients with 
heart failure.18 The intervention included quarterly phone calls to the patient from a nurse. At 1 
year, medical resource use and costs were similar across both groups. To increase the sample 
size for validation testing, we combined patients from both groups. 
To demonstrate how the model could be used to evaluate the cost-effectiveness of a 
disease management program, we included the 86 patients from CHIME in the standard care 
group. Then, we modeled 3 hypothetical scenarios representing programs that could increase 
proportions of patients in NYHA class II and increase use of evidenced-based medications. For 
program costs in scenario A, we computed the cost per patient per month in CHIME using the 
TEAM-HF Costing Tool.4 
 
Internal Validation in HF-ACTION 
Several statistical associations embedded in the TEAM-HF model were derived from HF-
ACTION.19 Thus, comparisons between estimates from the model with estimates from HF-
ACTION represent an internal validation test. Because observed resource use and outcomes were 
similar between groups in the trial, baseline characteristics were pooled across study groups and 
modeled over 2 years. 
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SCD-HeFT 
The economic evaluation of the Sudden Cardiac Death in Heart Failure Trial (SCD-
HeFT) provides an opportunity to compare estimates over a longer time horizon (20). SCD-
HeFT was a randomized trial of 2521 patients with symptomatic heart failure that found a 
statistically significant reduction in all-cause mortality among patients who received a single-
lead implantable cardioverter-defibrillator (ICD), compared with patients who received medical 
therapy or placebo. Median follow-up was 45.5 months. 
 
Funding/Support 
Development of the TEAM-HF Cost-Effectiveness Model was supported by grant 
5R01NR011873-02 from the National Institute of Nursing Research. The development and 
content of the TEAM-HF economic tools are solely the responsibility of the authors and do not 
necessarily represent the official views of the National Institute of Nursing Research or the 
National Institutes of Health. The trials used for validation purposes were supported separately. 
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Results 
CHIME  
In CHIME, patients were hospitalized an average of 1.3 times, had 0.5 emergency 
department visits, and had 3.1 outpatient visits (Table 2). By comparison, our model estimated 
1.1 hospitalizations, 1.0 emergency department visits, and 13.9 outpatient visits. Mean total costs 
estimated using patient-level data from CHIME were similar to mean total costs estimated with 
the TEAM-HF model ($23,861 vs $23,621) when all levels of uncertainty were varied 
stochastically. When parameter estimates were modeled deterministically, the point estimate was 
$19,622. 
To evaluate potential disease management programs, we assumed that the intervention in 
scenario A increased the proportion of patients with NYHA class II by 10 percentage points and 
the use of evidence-based medications increased by 5 percentage points. Intervention costs in 
scenario A included initiation costs of $70 and maintenance costs of $59 per patient per month 
for 1 year. Compared with standard care, mean total costs in scenario A increased by $1393 and 
QALYs increased by 0.2, corresponding to an incremental cost-effectiveness ratio of $6128 per 
QALY (Table 3). Scenarios B and C represent a higher-cost program with $2000 initiation costs 
plus ongoing costs of $200 per patient per month. With the same level of effectiveness as 
scenario A, the incremental cost-effectiveness ratio increased to $64,865 per QALY in scenario 
B. However, with greater effectiveness in scenario C, the higher cost of the program is offset by 
greater gains in QALYs (0.4), resulting in an incremental cost-effectiveness ratio of $29,701 per 
QALY. 
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HF-ACTION 
Observed estimates of medical resource use in HF-ACTION and estimates from our 
model were similar (Table 4). In HF-ACTION, patients were hospitalized an average of 2.0 
times, visited the emergency department or urgent care clinic 1.6 times, and had 30.6 outpatient 
visits. Based on the TEAM-HF model, patients would have been expected to have an average of 
2.1 hospitalizations, 1.9 emergency department or urgent care visits, and 26.3 outpatient visits. 
Total costs were also similar between estimates based on empirical data ($46,361) and modeled 
estimates ($48,098). Observed survival at 2 years was 83.4% in HF-ACTION compared to a 
modeled estimate of 79.6%. 
 
SCD-HeFT  
Five-year estimates of resource use and total costs generated with the TEAM-HF model 
were higher than reported for SCD-HeFT (20) in the ICD and placebo groups (Table 5). 
However, the estimated differences in mean costs at 5 years were similar: $23,472 with the 
TEAM-HF model and $27,141 in SCD-HeFT. Five-year survival predicted with the model was 3 
to 4 percentage-points lower than reported for SCD-HeFT. Nevertheless, 5-year survival gains 
and incremental cost-effectiveness ratios were similar for ICDs compared with standard care. 
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Discussion 
The TEAM-HF Cost-Effectiveness Model provides a flexible tool for the research and 
clinical communities to evaluate the long-term cost-effectiveness of disease management 
programs in heart failure. In addition to facilitating formal cost-effectiveness analyses, the model 
can be used for budget planning, projecting hospitalization rates, and quantifying life expectancy 
for a cohort of patients over a time period specified by the user. For example, the model could be 
used by health systems to predict cost offsets with a given program or to demonstrate expected 
longer-term cost-savings for a payer for a program that increases costs in the short-term. The 
model’s flexibility also offers users the opportunity to represent different perspectives by 
specifying direct medical costs to represent the health care system perspective or payments to 
represent the payer perspective. 
We believe ours to be the first generalizable simulation model developed to evaluate 
clinical and economic outcomes of patient-centered programs in heart failure. Previous models 
were developed to evaluate specific interventions and were structured using NYHA class3,21 or 
hospitalization counts as health states.22 Such models are not publicly available and cannot 
account for a broader range of factors that disease management programs may affect. 
Furthermore, variations in methods and reporting hinders the ability to make valid comparisons 
across studies.1,23 With repeated use of a common model by different investigators, a collection 
of studies could develop to provide a body of evidence on which types of interventions targeting 
specific patient groups consistently provide better or worse value. In addition, individual 
stakeholders could apply the model to support local decision making by modifying unit costs, 
patient characteristics, changes in prognostic variables affected by an intervention, and the time 
horizon of interest. 
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Model Validity 
It is not possible to simply declare a model as “valid.”24 There are several types of 
validity, including face validity, internal validity, cross validity (between models), external 
validity, and predictive validity, with the latter 2 types being the strongest. Demonstration of an 
economic model’s external and predictive validity, particularly for resource use and costs, is 
limited by variations in practice patterns and unit costs across settings.24 Furthermore, for a 
model like TEAM-HF that can have multiple applications, numerous validation exercises across 
a range of interventions across various patient populations, outcomes, and time horizons may be 
necessary. In fields such as diabetes, where multi-application simulation models were initially 
developed more than a decade ago, the relative strengths and limitations of these models are only 
now becoming understood.25 
In our examination of the model’s internal validity, we found that modeled estimates of 
resource use and mortality were consistent with empirical estimates from HF-ACTION. The 
findings of the 2 external validation tests were also promising. Our modeled estimates of 
hospitalizations were similar to CHIME, but modeled estimates of emergency department and 
outpatient visits were higher. The discrepancy can be attributed to differences in the scope of 
emergency department and outpatient visits included in the analysis. In CHIME, patients 
reported emergency department visits and outpatient physician visits associated with heart 
failure, whereas the TEAM-HF model includes all-cause visits to all health care providers (as 
collected in HF-ACTION). Compared with claims-based analyses in which all outpatient visits 
are considered (approximately 14 to 20 per year for patients with type 2 diabetes26; 
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approximately 18 to 22 per year for patients with atrial fibrillation27), the TEAM-HF model 
produces counts of similar magnitude. 
SCD-HeFT provided an opportunity to examine the model’s external validity over a 
longer time horizon. Cost data were not available in SCD-HeFT over a 5-year time frame for all 
patients, and partitioned estimators were used to adjust cost estimates to account for censoring. 
Because this approach did not account for higher rates of medical resource use that occurs with 
disease progression, one could expect costs from SCD-HeFT to be lower than costs from the 
model. Although reported 5-year costs in SCD-HeFT were lower than predicted with the TEAM-
HF model, the CIs from the TEAM-HF model included the point estimates from SCD-HeFT, and 
the estimated differences in 5-year survival were similar between analyses. We believe the 3 sets 
of validation tests indicate that the resource use, cost, and survival estimates generated with the 
TEAM-HF model demonstrate respectable internal and external validity. 
 
Variability 
Across the simulations, we generally observed higher point estimates for costs and 
resource use when simulations were varied stochastically. This occurs because high counts (ie, 
outliers) of resource use are sometimes generated with stochastic sampling, which better 
represents empirical distributions of resource use. Thus, we expect that stochastic sampling will 
better represent variability that can be expected in real-world situations. In addition, recognition 
that costs and survival may substantially vary in cohorts with small sample sizes is important. 
The literature includes many small studies of disease management programs that reported cost 
savings over a short time period. Such findings could be attributable to one or more high-cost 
outliers in the comparison group and would not likely be replicated if the study was repeated. 
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The TEAM-HF model could be used to evaluate whether observed differences in resource use, 
costs, and survival could be expected, given the impact of the disease management program on 
the prognostic factors represented in SHFM scores. 
 
Limitations 
Although we believe this model could prove to be a valuable resource, its users should be 
aware of its limitations. First, because HF-ACTION largely enrolled patients with NYHA class 
II and III heart failure, the statistical relationships between SHFM scores and resource use and 
health utilities that are embedded in the model will be less precise for individuals with more 
advanced disease. Nevertheless, by integrating end-of-life costs incurred by 339 HF-ACTION 
participants who died,15 our model incorporates high rates of resource use incurred during this 
period. In addition, resource use patterns in HF-ACTION may not be representative of other 
settings. Nevertheless, clinical sites in HF-ACTION included both academic and nonacademic 
institutions. Users should also recognize that the treatment effects for medications and devices 
embedded in the SHFM are based on randomized clinical trials. Therefore, when proportions of 
patients treated with evidence-based medications are modeled, those proportions should 
represent individuals who adhere to their treatments at a level similar to what would be observed 
in a clinical trial, not the proportions of patients prescribed specific medications. Lastly, although 
the SHFM offers several advantages, it does not include some variables found to be predictive of 
mortality in other prognostic models, such as B-type natriuretic peptide level.28 
We plan to expand the model to incorporate other prognostic models to allow users to 
perform sensitivity analyses or choose the prognostic model that includes variables that best 
capture the intermediate effects of a given disease management program. In the near term, we 
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hope that the model proves useful to researchers and health care managers in evaluating the costs 
and outcomes associated with disease management programs in heart failure. 
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Figure Legends 
 
Figure 1. Survival Curves and Mean Survival Estimates for Integer Seattle Heart Failure Model 
Scores 
 SHFM Score (ζ) 
 –1 0 1 2 3 
Expected survival, y 11.53 8.07 5.14 2.93 1.48 
95% CI      
  N = 100 (10.51-12.55) (7.22-8.92) (4.50-5.78) (2.51-3.35) (1.24-1.72) 
  N = 1000 (11.21-11.85) (7.80-8.34) (4.94-5.34) (2.80-3.06) (1.40-1.56) 
 
 
Figure 2. Cause-Specific Hazard for Death (Upper Panel) and Cause-Specific Probability of 
Death (Conditional on Having Died at the Time Indicated by the Time Axis) as a Function of an 
Initial Seattle Heart Failure Model Score (Lower Panel) 
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Table 1. User-Defined Inputs for the TEAM-HF Cost-Effectiveness Model  
Input Page Parameters (Options) 
General information Scenario name 
 Scenario comments 
 Study design (parallel groups, single cohort, hypothetical) 
 Group name* 
 Group sample size* 
 Length of observation† 
Observed resource use and death*† Counts of cardiovascular procedure-related hospitalizations; 
medically treated heart failure hospitalizations; non-heart failure 
hospitalizations; emergency department visits; outpatient visits 
 Number of patients who died 
Clinical characteristics*‡ Age 
 Sex 
 Weight 
 New York Heart Association class 
 Systolic blood pressure 
 Ejection fraction 
 Ischemic failure etiology 
Laboratory measurements*‡ Percent lymphocytes 
 Serum sodium 
 Total cholesterol 
 Hemoglobin 
 Uric acid 
Diuretics*‡ Proportion of patients receiving diuretics, and daily doses for each 
of the following medications: furosemide, bumetanide, torsemide, 
metolazone, hydrochlorothiazide 
Medications and devices*‡ Proportions of patients treated with β-blocker, aldosterone 
antagonist or potassium-sparing diuretic, ARB, ACE inhibitor, 
biventricular pacemaker, ICD, biventricular ICD 
Unit costs 
 
Cost per month for β-blocker, aldosterone antagonist or 
potassium-sparing diuretic, ARB, ACE inhibitor, diuretic 
 Cost per event for cardiovascular procedure-related 
hospitalization, medically treated heart failure hospitalization, 
non-heart failure hospitalization, emergency department visit, 
outpatient visit 
Disease management program characteristics Time period for intense and maintenance phases of the program 
 Program cost per patient upon initiation 
 Program cost per patient per month during intense and 
maintenance phases of program 
Simulation options Time horizon 
 Discount rates 
 Select output for resource use counts, costs, survival, and 
incremental cost-effectiveness ratios 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; ICD, implantable 
cardioverter-defibrillator. 
* Inputs for both the intervention and comparison groups. 
† Applies to parallel group design only. 
‡ Variables included in computation of Seattle Heart Failure Model scores. 
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Table 2. One-Year Estimates of Resource Use and Costs from CHIME and the TEAM-HF Cost-Effectiveness Model 
Outcome CHIME TEAM-HF Cost-Effectiveness Model 
  Stochastic* Deterministic† 
Resource use, total count (95% CI)‡    
Hospitalizations 109 (84-140) 98 (30-252) 79 (73-88) 
Emergency department or urgent care visits 45 (30-63) 87 (43-155) 82 (79-87) 
Outpatient visits 269 (249-291) 1198 (733-1770) 1231 (1179-1288) 
Resource use, mean (95% CI)‡    
All-cause hospitalizations 1.3 (1.0-1.6) 1.1 (0.3-2.9) 0.9 (0.8-1.0) 
Emergency department or urgent care visits 0.5 (0.4-0.7) 1.0 (0.5-1.8) 1.0 (0.9-1.0) 
Outpatient visits 3.1 (2.9-3.4) 13.9 (8.5- 20.6) 14.3 (13.7-15.0) 
Costs, mean (95% CI), $‡    
All-cause hospitalizations 21,676 (16,139-28,493) 20,751 (6345-53,302) 16,774 (15,358-18,548) 
Heart failure hospitalizations 9104 (6503-13,006) 4324 (1322-11,108) 3496 (3201-3865) 
Non-heart failure hospitalizations 5379 (3631-7800) 7431 (2272-19,089) 6007 (5500-6642) 
Cardiovascular procedures 7192 (3320-11,619) 8995 (2750-23,105) 7271 (6658-8040) 
Medications 199 (181-216) 140 (120-153) 148 (140-157) 
Emergency department or urgent care visits 660 (440-924) 1282 (631-2274) 1210 (1154-1274) 
Outpatient visits 325 (3014-351) 1449 (886-2140) 1488 (1426-1557) 
Total 22,861 (17,357-29,750) 23,621 (8,237-57,535) 19,622 (18,093-21,516) 
* All levels of uncertainty modeled as stochastic except unit costs. 
† All levels of uncertainty modeled as deterministic except patient profiles. 
‡ Confidence intervals for CHIME were estimated using the bias-corrected nonparametric bootstrap method. 
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Table 3. Estimated Cost-Effectiveness of Hypothetical Disease Management Programs 
Variable Standard Care Scenario A* Scenario B* Scenario C* 
Inputs 
Program costs — $70 initiation plus $59 per  
patient per month for 12 
months 
$2000 initiation plus ongoing cost of $200 per patient per month 
NYHA class, %    
I 0 Increase 0 percentage points Increase 0 percentage points 
II 51 Increase 10 percentage points Increase 20 percentage points 
III 38 Decrease 5 percentage points Decrease 10 percentage points 
IV 11 Decrease 5 percentage points Decrease 10 percentage points 
Evidence-based medications, %    
Beta-blockers 80 Increase 5 percentage points Increase 15 percentage points 
Aldosterone antagonists 41 Increase 5 percentage points Increase 15 percentage points 
Angiotensin receptor blockers 15 Increase 5 percentage points Increase 15 percentage points 
ACE inhibitors 48 Increase 5 percentage points Increase 15 percentage points 
Results† 
Lifetime costs 170,279 (139,843 to 201,468) 171,672 (141,593 to 203,576) 185,021 (139,843 to 201,468) 185,890 (152,506 to 219,375) 
Difference in costs‡ — 1393 (–42,048 to 46,083) 14,742 (–31,180 to 60,044) 15,464 (–29,534 to 59,514) 
Life-years 5.8 (2.5 to 9.9) 6.0 (2.7 to 9.9) 6.3 (2.9 to 10.2) 
Difference in life-years‡ — 0.2 (–0.9 to 1.3) 0.5 (–0.6 to 1.6) 
QALYs 4.6 (1.9 to 8.1) 4.8 (2.0 to 8.2) 5.0 (2.2 to 8.4) 
Difference in QALYs‡ — 0.2 (–0.7 to 1.1) 0.4 (–0.5 to 1.4) 
ICER, $ per QALY§ — $6128 $64,865 $29,701 
Abbreviations: ICER, incremental cost-effectiveness ratio; NYHA, New York Heart Association; QALY, quality-adjusted life-year. 
* All levels of uncertainty modeled as stochastic except unit costs. Dominant = less costly, more QALYs; dominated = more costly, fewer QALYs. 
† Discounted estimates reported. 
‡ Hypothetical program – standard care. 
§ Dominant – dominated. 
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Table 4. Resource Use, Costs, and Survival from HF-ACTION and the TEAM-HF Cost-Effectiveness Model 
Outcome HF-ACTION TEAM-HF Cost-Effectiveness Model 
  Stochastic* Deterministic† 
Resource use, mean (95% CI)‡    
Hospitalizations 2.0 (1.9-2.1) 2.1 (0.8-4.3) 1.9 (1.8-1.9) 
Emergency department or urgent care visits 1.6 (1.5-1.8) 1.9 (1.2-2.7) 1.9 (1.9-2.0) 
Outpatient visits 30.6 (29.3-32.0) 26.3 (18.0-32.9) 28.9 (28.7-29.2) 
Medical costs, mean (95% CI), $‡§||    
Hospitalizations and physician fees 41,947 (38,210-46,354) 42,552 (16,291-45,072) 38,982 (38,332-39,664) 
Emergency department or urgent care visits 1763 (1607-1957) 2731  (1698-3854) 2796 (2772-2821) 
Outpatient visits 2651 (2536-2776) 2815 (1931-3523) 3097 (3073-3121) 
Total 46,361 (42,536-50,856) 48,098 (19,979-95,799) 44,874 (44,180-45,604) 
Survival, % (95% CI) 83.4 (81.9 - 84.9) 79.6 (51.3 - 94.5) 99.9¶ 
* All levels of uncertainty were modeled stochastically. 
† All levels of uncertainty were modeled as deterministic except patient profiles. 
‡ CIs for HF-ACTION were estimated using the bias-corrected nonparametric bootstrap method. 
§ Costs updated to 2013 US dollars using the Consumer Price Index for Medical Care and a discount rate of 0%. 
|| Medication costs were excluded due to costing based on branded medications in HF-ACTION. 
¶ When survival time is modeled deterministically, only 0.1% of patient profiles corresponded to an expected period of survival less than 5 years. 
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Table 5. Five-Year Estimates From SCD-HeFT and the TEAM-HF Cost-Effectiveness Model 
 
Outcome 
SCD-HeFT Economic Evaluation TEAM-HF Cost-Effectiveness Model* 
ICD Placebo Difference ICD Placebo Difference 
Resource use, mean       
Hospitalizations 2.8 2.7 0.1 4.0 4.4 –0. 4 
Emergency department visits 1.2 1.4 –0.1 3.9 4.1 –0.2 
Outpatient visits 18.9 19.7 0.8 56.7 55.5 –1.2 
Total medical costs, mean (95% CI), $† 88,630 61,489 27,141 122,624 
(76,827-179,007) 
99,152 
(50,278-156,255) 
23,472 
(13,964-31,959) 
5-year survival, proportion 0.65 0.59 0.06 0.61 0.56 0.05 
5-year ICER (95% CI), 
$/life-year saved 
182,460‡ 166,571 (65,284-3,653,130) 
Abbreviation: ICER, incremental cost-effectiveness ratio. 
* All levels of uncertainty modeled as stochastic. 
† Costs reported in Mark et al. (20) updated to $2013 using the Consumer Price Index for Medical Care. 
‡ Re-estimated by applying life-years saved (0.149) derived from the 5-year incremental cost-effectiveness ratio reported in Mark et al. (20). 
 
  
 
  
 
 
